Publix recalls baby food pouches after testing finds elevated levels of lead
The supermarket chain Publix has recalled fruit and vegetable baby food sold in eight states because product testing found elevated levels of lead, according to federal health officials.
Publix recalled 4-ounce Greenwise Pear, Kiwi, Spinach & Pea Baby Food pouches sold at more than 1,400 stores.
The pouches were produced by Bowman Andros, a French company with a manufacturing plant in Mount Jackson, Virginia, according to the company's website. Publix issued the voluntary recall on May 9, but it wasn't added to the U.S. Food and Drug Administration recall list until late Thursday.
The potential contamination was flagged by officials in North Carolina, the state that first identified a 2023 lead poisoning outbreak linked to tainted applesauce pouches that sickened more than 500 U.S. children.
Routine sampling of the baby food pouches found lead levels at 13.4 parts per billion, according to North Carolina agriculture officials. That exceeds the FDA's recommended limit of 10 parts per billion for such products intended for babies and young children.
Publix said all the potentially contaminated products have been removed from store shelves. No illnesses have been reported, the company said. Customers can return the pouches to local stores for full refund.
This is the second baby food pouch recall because of potential lead contamination in two months. In March, Target recalled more than 25,000 packages of its store brand Good & Gather Baby Pea, Zucchini, Kale & Thyme Vegetable Puree because of elevated lead levels.
North Carolina collaborates with the FDA to conduct routine testing of food products, officials said.
In 2023, state health officials investigated reports of lead poisoning in four children who consumed WanaBana apple cinnamon fruit puree. Those findings led to the detection of a nationwide outbreak linked to the pouches, which were widely sold in Dollar Tree and other stores. Tests showed they contained lead at levels 2,000 times higher than the FDA's maximum recommended level, as well as chromium.
Federal health officials eventually identified 566 cases of confirmed, probable or suspected cases of lead poisoning tied to the pouches in 44 states.
The U.S. Centers for Disease Control and Prevention's childhood lead poisoning program investigated the applesauce outbreak and coordinated state and federal response. However, the program was eliminated in April as part of federal funding cuts under the Trump administration.
CDC officials didn't say whether or how the agency would respond to a similar outbreak now. A spokesperson said the agency is aware of the Publix baby food recall but hasn't been asked to assist with any investigation.
There is no safe level of lead exposure, according to CDC. While the heavy metal is toxic to people of all ages, it can be especially harmful to children, causing damage to the brain and nervous system and slow growth and development.
Heavy metals like lead can get into food products from soil, air, water or industrial processes, according to the American Academy of Pediatrics.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy' Penny Stocks
Big names may rule the headlines, but many of the market's future stars begin as under-the-radar underdogs. While Wall Street focuses on the trillion-dollar club – think the 'Magnificent 7' – some of the most compelling opportunities are tucked away in the bargain bin, trading for $5 or less. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter These low-priced stocks – known as penny stocks – often operate in high-growth corners of the market, and when the right catalyst hits, whether a breakthrough innovation or a disruptive product, they can deliver explosive gains. That said, not every penny stock is a diamond in the rough. Some linger at the bottom for good reason, dragged down by shaky fundamentals or challenges that may be too big to overcome. So, how do you spot the ones ready to take off? That's where Wall Street's analysts come into play. Using TipRanks' database, we've zeroed in on two standout penny stocks earning high marks from analysts. Both boast a 'Strong Buy' consensus rating and substantial upside potential – with one eyeing a nearly 590% surge. Let's take a closer look and find out what the optimism is all about. Skye Bioscience (SKYE) We'll start with Skye Bioscience, a biopharmaceutical researcher developing new treatments for metabolic disorders, with a particular focus on obesity. This is a fertile area for an innovative biotech firm – the global anti-obesity drug market is projected to grow from $12.8 billion in 2025 to $104.9 billion by 2035, reflecting a 21.1% CAGR over the forecast period. Beyond its prevalence, obesity contributes to a host of physical and mental health complications, creating a need for effective therapies. To meet this need, Skye is taking a novel approach to weight loss by targeting the CB1 pathway through selective inhibition. Its lead candidate, nimacimab, is a peripherally restricted CB1 inhibitor, specifically designed to sidestep the central nervous system side effects that limited earlier CB1-targeting drugs. Now in a Phase 2a clinical trial, CBeyond, nimacimab is approaching a key catalyst: the release of topline data expected in late Q3 or early Q4 2025. In earlier testing at the preclinical and Phase 1 stages, nimacimab demonstrated encouraging results. In an April update, Skye reported that in a mouse model, combining nimacimab with tirzepatide (a dual GLP-1/GIP agonist) resulted in over 30% weight loss after 25 days. Nimacimab alone produced a 23.5% reduction, comparable to monotherapies with tirzepatide or monpelabant. Supporting its safety profile, multiple reviews by the Data Safety Monitoring Committee have been completed with no concerns raised to date. Looking ahead to future clinical development and potential commercialization, Skye has partnered with Arecor Therapeutics to explore a new formulation of nimacimab. Under the agreement, Skye will fund the development using Arecor's proprietary formulation platform and holds an option to license the resulting formulation, including associated intellectual property and commercialization rights. With SKYE trading at $2.16, JMP analyst Jonathan Wolleben sees a big opportunity brewing – especially with a topline data readout just around the corner. 'We continue to like nimacimab's position in the CB1 inhibitor pipeline as a truly peripherally restricted inhibitor, and we view the rapid and over-enrollment of CBeyond as reflective of the high patient enthusiasm for the differentiated mechanism in the obesity pipeline. We think CBeyond is well-designed to answer key safety and efficacy questions, and we like that the DSMC reviews have not raised any concerns to date. Given the history of mechanism, safety will be top of mind for investors. Recall that SKYE saw no neuropsychiatric side effects in its prior Phase 1 and no accumulation in the CNS or brain in non-human primates… We'll see 26-week weight loss data from SKYE's Phase 2a trial in late 3Q/early 4Q where the study is powered to detect an 8% pbo-adj. difference which we would view as a win and should drive shares higher,' Wolleben opined. Backing his bullish case, Wolleben rates SKYE a Buy with a $16 price target, implying a massive one-year upside potential of 594%. (To watch Wolleben's track record, click here) The overall view of SKYE is even more bullish than that. The stock's Strong Buy consensus rating is unanimous, based on 6 positive analyst reviews, and the $17.20 average price target suggests a whopping 696% premium over the next 12 months. (See SKYE stock update) PolyPid (PYPD) Surgery is difficult for patients, even under the best conditions, with infection, inflammation, and pain among the potential post-operative complications. PolyPid, a clinical-stage biopharmaceutical company, is working to address these issues through improved medication delivery. The company has developed a proprietary drug delivery platform called PLEX (polymer-lipid encapsulation matrix), designed to provide targeted, localized, and sustained release of post-operative medications. This layered system – built from alternating polymers and lipids – can deliver a wide range of therapeutic agents, including small molecules, proteins, peptides, and nucleic acids. PLEX is engineered to maintain drug potency and minimize toxicity, enabling controlled release over extended periods, potentially lasting several months. Leveraging this platform, PolyPid developed its lead product candidate, D-PLEX100, which has been evaluated in two Phase 3 clinical trials – SHIELD I and SHIELD II – focused on preventing surgical site infections following abdominal colorectal procedures. While the SHIELD I study did not meet its primary endpoint, PolyPid announced positive topline results from SHIELD II earlier this month. The trial achieved both its primary and key secondary endpoints, demonstrating statistically significant benefits in 798 patients undergoing large abdominal surgeries. With these results, the company is preparing for a potential New Drug Application (NDA) submission in early 2026 and views the data as a catalyst for advancing global partnership discussions. To support its next steps, the company also secured up to $26.7 million in funding through the exercise of outstanding warrants, extending its cash runway beyond the expected FDA approval window for D-PLEX100. Roth Capital analyst Boobalan Pachaiyappan views the SHIELD II results as a turning point – not only confirming clinical efficacy but also laying out a compelling path toward regulatory approval and a sizable market opportunity for D-PLEX100. 'D-PLEX100 delivered efficacy across the board on all secondary endpoints… Although a comprehensive safety data analysis was not presented, given that only top-line data are available, the lack of safety signals suggests that D-PLEX100 is safe and tolerable, exhibiting a profile consistent with previous studies, and is suitable for treating SSI patients… We expect D-PLEX100 FDA approval in 2H26, with the initial launch in 2027 focusing on colorectal surgeries (partner: TBD) and the EU/U.K. launch in 2028 (partner: ADVANZ Pharma; private), with subsequent launches within the broader abdominal procedures category (~4.5M surgeries) in the following years… Our models suggest >$800M in peak sales in 2035, with PYPD revenue >$200M (net royalty rate: 25%),' Pachaiyappan wrote. Pachaiyappan quantifies his positive stance with a Buy rating on PYPD and a $9 price target that points toward a one-year gain of 174%. (To watch Pachaiyappan's track record, click here) Overall, there are 5 recent analyst reviews on record for PYPD shares, and the 4-to-1 split, favoring Buy over Hold, gives the stock its Strong Buy consensus rating. The shares are priced at $3.28, and their $11.50 average target price suggests an upside of 250% on the one-year horizon. (See PYPD stock forecast) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Sign in to access your portfolio
Yahoo
37 minutes ago
- Yahoo
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
The average healthcare stock has a yield of just 1.7%. Medtronic's dividend yield is 3.3%. Alexandria Real Estate Equities' yield is 7.4%. 10 stocks we like better than Medtronic › The healthcare sector isn't exactly known for offering huge yields, with Health Care Select Sector SPDR (NYSEMKT: XLV) offering a yield of just 1.7%. If dividend investors take some time to dig into the sector, however, they can do much better. For example, Medtronic (NYSE: MDT) has a 3.3% yield today, and Alexandria Real Estate Equities (NYSE: ARE) is offering a yield of 7.4%. Here's what you need to know about each of these high-yield healthcare stocks. Medtronic makes medical devices. It is one of the largest competitors in the space, making products across the cardiovascular, neuroscience, medical surgical, and diabetes categories. It has a leading position in each of the areas in which it operates, and it operates on a global scale. That said, the last few years haven't been the best ones for the company. Innovation, which is highly important in the healthcare space, can be lumpy. And given Medtronic's size, the business has become a little cumbersome. Growth has stalled out, and profitability has come under pressure. Investors have focused on the negatives pushing the shares lower and the dividend yield up toward the high end of Medtronic's historical yield range. If you are a dividend investor that thinks in decades and not days, however, this is likely to be an investment opportunity. The company's innovation pipeline is starting to turn into new-product introductions. As new products gain traction, financial performance is likely to improve. And management has been working to streamline the business with cost cuts and a move to refocus on its most profitable operations. To that end, the company is set to spin off its lower-margin diabetes division in 2026. The move is expected to be immediately accretive to earnings, and the dividend policy isn't expected to change. All in, Medtronic is doing what it needs to do to get back on the growth path. And that should support continued dividend increases; the medical device maker only has two years to go before it hits Dividend King status (50+ years of annual dividend increases). June could be an opportune time to buy the stock hand over fist. Alexandria is a real estate investment trust (REIT), which seems pretty far away from healthcare. Its primary focus is on office properties, which also seems a bit removed from healthcare. The key here is that the REIT owns biomedical research facilities, which combine research space and office space in one property. Both are important to each other since the research takes place in specialized space, while the analysis of that research takes place in a normal office environment. Alexandria is one of the largest pure play medical research REITs you can buy. Alexandria counts some of the largest and most important medical research groups as tenants, from both the private side of the equation and the government side. However, like any landlord, the REIT's revenues will be impacted by the occupancy levels of its properties. And those rise and fall over time. Right now, occupancy is relatively weak, dropping to 91.7% at the end of the first quarter of 2025 from 94.6% at the end of 2024. Swings like this happen from time to time, but Wall Street is treating Alexandria as if its dividend is at a material risk of being cut. Only the funds from operations (FFO) payout ratio in the first quarter was a fairly strong 57%. There's room for adversity before a dividend cut would be in order. To be fair, office properties, and particularly highly specialized office properties, tend to have higher operating costs than other real estate assets. But it seems highly likely that Alexandria will manage its way through this weak patch and continue to extend its 15-year streak of annual dividend increases. For income lovers, this healthcare REIT is worth a deep dive in June. The average healthcare stock has an uninspiring dividend yield. But the average is made up of many different companies, some of which actually have very attractive dividend yields. That list includes industry-leading companies like Medtronic and Alexandria Real Estate. You might just want to pick up shares in one, or both, of these high yielders before June is over after you get to know them a little better. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Alexandria Real Estate Equities. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. 2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
I can think of so many things I love. I'll bet you can, too, and it's empowering
Most friendships include the occasional commiseration conversation. When we're young, those discussions center on homework or dating or parental interference. Eventually, we graduate to work disputes, financial woes and relationship friction. Alas, I've reached the age at which those conversations are constant rather than occasional, and the sources of angst generally are weight gain, politics and maladies. I pride myself on being a positive person, but sometimes waking up with aching knees and a bum shoulder can get depressing. Add to that a volatile stock market, sketchy medical bills and a car issue that may, or may not, be covered by warranty, and it's easy to wallow. Then a friend shared this quote: 'Focus on the things you are for, not the things you are against. Many people spend large chunks of their day thinking about what they hate. They are always telling you about something they dislike: this food, that subject, this political party, that co-worker. You are more than your frustrations. Build your identity around what you love.' It's attributed to James Clear, author of 'Atomic Habits,' though the Google could neither confirm nor deny its origins. Regardless, the message is empowering. So here goes, a few things I love: — I've taken up swimming for the second summer. I've worked my way up to swimming three times a week, one mile at a time. I've learned not to plan anything within two hours of a swim session, because it takes me that long to stop sweating. The thing I love most about swimming? I barely feel those achy joints anymore. — The babies have grown up and gone to college. The toddlers have toddlers of their own. That's how long my family has been gathering for our annual summer reunions. You'd think we'd be tired of them by now, but we're not. This year's trip is three weeks out, and the phone calls and group texts are in full swing as we plan meals, field trips and cabin assignments. I've also started stocking up on Publix BOGOs. (Yay for free Pop-Tarts!) — I recently started driving a new-to-me car that came equipped with Apple CarPlay. How have I driven four and a half decades without being able to shuffle my Pandora stations? Any drive is better when it features Billy Joel, Bonnie Raitt, Tyler Childers, the Partridge Family, Marcia Ball and Willie Nelson. It's also kind of awesome having an on-screen map that tells me when I'm 12 minutes from home. — After 21 years of marriage, my husband knows I'm dead calm when I've sliced off the tip of my finger while cutting potatoes. Blood-curdling screams are saved for flying roaches. — I have solved one of the world's greatest mysteries: Where errant socks go. Turns out we're not paranoid. The washing machine really does eat them. At least mine does. Socks like to get caught in the rubber gasket that seals my front-load washer. Sorry, pups. Didn't mean to wrongly accuse you. — And while we're talking about pups, my life is good. There are people who are literally allergic to dogs. — I love having friends who run the gamut when it comes to age, gender and political preferences. They make me smarter, and they make me laugh. They help me understand different perspectives, and they validate my beliefs. A life of homogeneity would be so dull. These are just a few of the things around which I want to build my identity. Now it's your turn. Will you focus on the things you love? Or will you let the things you hate define you? Suzy Fleming Leonard is a retired journalist who spent 25 years as a writer, editor and columnist at FLORIDA TODAY. Reach her at suzy@ This article originally appeared on Florida Today: When you fill your life with love, there's no room for hate | Leonard
